Back to News
Market Impact: 0.35
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Source: zacks.com
Healthcare & BiotechCompany Fundamentals
Krystal Biotech reported early results for KB113 in a Gorlin syndrome study, with tumor regression observed in more than 80% of assessed lesions. The preliminary finding is encouraging, but the brief report provides no further efficacy, safety, or study-size details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
KRYS0.75
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated